Programme

DAY 1: MONDAY 24 SEPTEMBER 2018 (afternoon)

13:00    Introduction

SESSION 1: PERSONALISED MEDICINE – THE FUTURE OF DRUG DEVELOPMENT  

13:10    Talk 1: Academia’s perspective

13:30    Talk 2: Challenges of cancer heterogeneity for the development of personalized therapy

13:50    Talk 3: Industry Perspective

14:05    Talk 4: Industry Perspective (biotech)

14:20    Talk 5: Assessment of cancer immunotherapies – who benefits most? (HTA’s perspective)

14:40    Talk 6: Payer’s perspective

15:00     Talk 7: Patient Advocate’s perspective

15:20    Roundtable discussion (30’ with all presenters)

15:50     Coffee break (30’)

 

SESSION 2: CHALLENGES FOR ACCESS TO BIOMARKERS

16:20   Talk 1: In Vitro Diagnostics (IVD) – European Regulatory perspective (EMA)

16:40    Talk 2: Case Story

16:50    Talk 3: HTA perspective

17:10    Talk 4: Biomarker development for immunotherapy: a new chance

17:30    Talk 5: Patients’ Perspective

17:50    Talk 6: Industry Perspective (Biotech)

18:05     Talk 7: Industry Perspective

18:20    Roundtable discussion (30’ with all presenters)

18:50     End of Day 1

19:30    Networking Dinner at The Twelve Restaurant (Thon Hotel EU)

 

DAY 2: TUESDAY 25 SEPTEMBER 2017 (morning)

SESSION 3: THE WAY FORWARD

09:00     Talk 1: How to foster collaborations between drugs and diagnostic companies

09:20     Talk 2: The future of precision oncology

09:40    Talk 3: Payer’s Perspective: Sustainability of the Healthcare Systems

10:00     Talk 4: Potential of Real World Evidence for access to biomarkers

10:20     Roundtable discussion (30’ with all presenters)

10:50     Coffee break (30’)

 

11:20     European Commission Guidelines on HTA

11:40     Need for Harmonization?

 

SESSION 5: NEXT STEPS

12:00     Next steps to take together (roundtable) – 30 minutes

12:30    Lunch

 

ECPC session on HTA & Access to Innovative Oncology Drugs in Europe
Location: European Parliament

14:30    Two-hour session (programme to be announced soon)

16:30     End of the Day